<DOC>
	<DOCNO>NCT00002375</DOCNO>
	<brief_summary>The purpose study see safe effective treat HIV-infected patient indinavir ( IDV ) plus nelfinavir ( NFV ) , 2 anti-HIV medication . It think IDV plus NFV safe drug combination treat HIV .</brief_summary>
	<brief_title>Safety Effectiveness Giving Indinavir Nelfinavir HIV-Infected Patients</brief_title>
	<detailed_description>It hypothesize administration indinavir nelfinavir generally safe well tolerate . This parallel , time-lagged , 2-stage , multiple-dose , 24-week study HIV-1 seropositive patient . In 3-week , randomize , double-blind phase Stage A , patient receive either indinavir plus nelfinavir ( Group A1 : 9 patient ) indinavir placebo plus nelfinavir placebo ( Group A2 : 3 patient ) first week . In Week 2 , patient Group A1 nelfinavir dose increase . This dose escalation nelfinavir contingent upon patient complete 1 week study drug without experience Grade 3 bad toxicity and/or serious drug-related adverse event . Patients Group A2 continue receive placebo Week 3 , time receive indinavir plus nelfinavir ( initial dose ) , patient Group A1 continue indinavir plus nelfinavir ( escalate dose ) . At Week 4 patient Stage A ( include originally assign receive placebo ) receive open-label indinavir plus nelfinavir ( escalate dose ) remainder 24 week . After least 6 patient Stage A complete least 2 week therapy nelfinavir plus indinavir acceptable tolerability , Stage B begin . In 2-week , randomize , double-blind phase Stage B , patient receive either indinavir plus nelfinavir ( Group B1 : 9 patient ) indinavir placebo plus nelfinavir placebo ( Group B2 , 3 patient ) . After 2 week , patient Stage B ( include originally assign receive placebo ) receive open-label indinavir plus nelfinavir remainder 24 week .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Nelfinavir</mesh_term>
	<mesh_term>Indinavir</mesh_term>
	<criteria>Inclusion Criteria You may eligible study : Are HIVpositive . Have CD4 count least 100 cells/mm3 . Have plasma viral load ( level HIV blood ) least 30,000 copies/ml . Are least 18 year old . Exclusion Criteria You eligible study : Have ever treat protease inhibitor ( PIs ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2000</verification_date>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>HIV Protease Inhibitors</keyword>
	<keyword>Indinavir</keyword>
	<keyword>Nelfinavir</keyword>
	<keyword>Anti-HIV Agents</keyword>
</DOC>